Emoxipin (Mexidol): A Comprehensive Review of its Chemical Profile, Pharmacology, Clinical Applications, and Regulatory Status

1. Introduction to Emoxipin (Mexidol)

Emoxipin, more commonly encountered in clinical and research settings as its succinate salt, Mexidol, is a pharmaceutical agent that has garnered attention primarily for its antioxidant and antihypoxic properties.[1] The development and principal utilization of this compound have been concentrated in Russia and several Commonwealth of Independent States (CIS) countries, where it is recognized as a significant therapeutic agent.[1]

The drug was initially synthesized by L.D. Smirnov and K.M. Dumayev and subsequently underwent further development at prominent Russian research institutions, including the Institute of Pharmacology of the Russian Academy of Medical Sciences and the Russian Scientific Center of Bioactive Substances Safety.[1] Within the Russian pharmaceutical landscape, Mexidol (ethylmethylhydroxypyridine succinate) holds the status of a reference, or original, drug, underscoring its established presence and perceived therapeutic value in that region.[2] This standing is further highlighted by accolades such as the Prize of the Government of the Russian Federation, awarded in 2003 for its development and introduction in the treatment and prevention of cerebrovascular diseases.[2]

The therapeutic rationale for Emoxipin/Mexidol is rooted in its purported multimodal mechanism of action, which is aimed at mitigating pathological processes associated with oxidative stress, hypoxia, and ischemia.[2] This broad mechanistic profile has led to its investigation and use across a diverse range of clinical conditions.

A notable aspect of Emoxipin/Mexidol is the geographical concentration of its development, research, and clinical application. While it is a well-established therapeutic in Russia and some CIS nations [1], it has not achieved comparable recognition or regulatory approval from major Western agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the breadth of indications it holds in Russia.[1] This divergence may reflect differences in regulatory requirements, clinical trial methodologies, or the interpretation of evidence regarding its risk-benefit profile. The status of Mexidol as a "reference original Russian drug" [2] and its governmental endorsements have likely fostered a substantial body of local research and clinical experience. However, the extent to which this evidence has been subjected to international peer review and meets the evidentiary standards of global regulatory bodies remains a critical point of consideration.

2. Chemical and Pharmaceutical Profile

Nomenclature

The compound Emoxipin (also referred to as Emoxypine) is chemically identified as 2-ethyl-6-methyl-3-hydroxypyridine.[11] However, in therapeutic applications, it is predominantly administered as its succinate salt, widely known by the trade name Mexidol. This form is chemically 2-ethyl-6-methyl-3-hydroxypyridine succinate or ethylmethylhydroxypyridine succinate.[1] The consistent use of the succinate salt in clinical contexts suggests that this form may offer advantages in terms of pharmaceutical properties such as stability, solubility, or bioavailability over the free base, a common strategy in drug development. Indeed, the succinate moiety itself is considered functionally significant.[2]

Chemical Structure and Properties

Table 1: Chemical Properties of Emoxipin and Emoxypine Succinate

Property	Emoxipin (Base)	Emoxypine Succinate (Mexidol)
IUPAC Name	2-ethyl-6-methylpyridin-3-ol	2-ethyl-6-methyl-3-pyridinol succinate (salt)
	11	16
Molecular Formula	C8​H11​NO	C12​H17​NO5​ (for the 1:1 salt)
	11	16
Molecular Weight	~137.18 g/mol	~255.27 g/mol (for the 1:1 salt)
	11	16
CAS Number	2364-75-2	127464-43-1
	11	16
Key Synonyms	Emoxypine, Epigid, Epygid, Methylethylpyridinol	Mexidol, Mexicor, Armadin Long, Ethylmethylhydroxypyridine succinate
	11	3
DrugBank ID	DB19172	DB19172 (refers to Emoxypine base, succinate is a salt form)
	11	29
ChemSpider ID	102688	109054
	13	16
PubChem CID	114681	109054 (for succinate salt, different from base CID)
	11	16

Emoxipin/Mexidol is described as a synthetic derivative of vitamin B6 (pyridoxine), sharing a similar 3-hydroxypyridine structure.[3] This structural relationship to a well-known vitamin is noteworthy, potentially hinting at interactions with vitamin B6-dependent pathways or influencing its tolerability profile, although such connections require substantiation through detailed mechanistic and safety data. The physical appearance of Mexidol is typically a white or almost white crystalline powder, soluble in water.[31]

Available Formulations and Strengths

Emoxipin/Mexidol is available in various formulations suitable for different clinical needs:

• Tablets: Commonly available in strengths such as 125 mg and as Mexidol Forte 250 mg tablets.[2]
• Solution for Injection: Prepared for intravenous (IV) and intramuscular (IM) administration, typically at a concentration of 50 mg/mL, available in 2 mL and 5 mL ampoules.[22]

3. Mechanism of Action

Emoxipin, particularly as its succinate salt Mexidol, is characterized by a multimodal mechanism of action, primarily encompassing antioxidant, antihypoxic, and membrane-protective effects.[1] This pleiotropic activity is attributed to the combined actions of its 2-ethyl-6-methyl-3-hydroxypyridine moiety and the succinate component.

Antioxidant Activity

The antioxidant properties of Emoxipin/Mexidol are central to its therapeutic rationale. It acts through several pathways:

• Direct Radical Scavenging: The compound directly inactivates free radicals and inhibits lipid peroxidation, a key process in cellular damage.[2]
• Enzyme Activity Enhancement: It increases the activity of endogenous antioxidant enzymes, notably superoxide dismutase (SOD) and glutathione peroxidase.[6]
• Nrf2 Pathway Activation: Mexidol demonstrates indirect antioxidant effects by upregulating the expression of the transcription factor Nrf2 (Nuclear factor erythroid 2-related factor 2) during ischemic conditions. Nrf2 plays a critical role in orchestrating cellular defense mechanisms against oxidative stress.[6]
• Iron Chelation: In vitro studies have suggested potential iron-chelating properties for emoxypine.[6]

Antihypoxic Activity

The antihypoxic effects of Mexidol are significantly attributed to its succinate component.[2] Succinate is a crucial intermediate in the Krebs cycle and can support cellular energy production under conditions of oxygen deficiency by fueling the succinate oxidase pathway.[2] Furthermore, succinate acts as a ligand for the GPR91 receptor (also known as SUCNR1), a G protein-coupled receptor. Activation of GPR91 can initiate signaling cascades that enhance cellular resistance to hypoxia and may regulate the release of pro-angiogenic factors.[2] Mexidol also promotes compensatory activation of aerobic glycolysis and reduces the inhibition of oxidative processes in the Krebs cycle during hypoxia, thereby increasing cellular levels of ATP and creatine phosphate.[21]

Membrane-Protective Effects

Emoxipin/Mexidol exerts significant membrane-protective actions:

• It stabilizes cellular membranes, reduces membrane viscosity, and enhances membrane fluidity.[2] This is partly achieved by increasing the proportion of polar lipid fractions, such as phosphatidylserine and phosphatidylinositol, and decreasing the cholesterol-to-phospholipid ratio within the membrane.[2]
• The drug modulates the activity of various membrane-bound enzymes, including adenylate cyclase, acetylcholinesterase, and phosphodiesterase. It also influences receptor complexes such as benzodiazepine, GABA, and acetylcholine receptors.[2] These interactions are thought to contribute to the preservation of the structural and functional integrity of biomembranes and affect neurotransmitter transport and synaptic transmission.

The dual-component nature of Mexidol, combining ethylmethylhydroxypyridine with succinate, is fundamental to its broad therapeutic profile.[2] The 3-hydroxypyridine moiety, with its structural similarity to pyridoxine (Vitamin B6), is likely the primary contributor to the direct antioxidant and membrane-stabilizing activities. Concurrently, the succinate component plays a vital role in the antihypoxic effects by supporting energy metabolism and activating specific succinate receptors (GPR91/SUCNR1). This combined action allows the drug to address cellular dysfunction arising from both oxidative damage and energy depletion, which are common features in many of its target indications.

Beyond direct radical scavenging, Mexidol's engagement with cellular signaling pathways, such as the Nrf2 pathway for antioxidant defense and the GPR91/SUCNR1 pathway for metabolic stress response, suggests a more profound and potentially sustained cellular protective effect.[2] This implies an active modulation of cellular adaptation mechanisms rather than merely passive neutralization of harmful molecules.

Neuroprotective and Nootropic Effects

The mechanistic actions of Emoxipin/Mexidol translate into several observed neuroprotective and nootropic (cognition-enhancing) effects:

• Reduction of glutamate excitotoxicity.[34]
• Restoration of neurotransmitter balance.[34]
• Improvement of neuronal energy status.[35]
• Modulation of neuronal GABA and acetylcholine receptor activity.[5]

The ability of Mexidol to alter membrane fluidity and interact with membrane-bound receptor complexes offers a plausible link between its physicochemical effects and its diverse CNS activities, including nootropic, anxiolytic, and anticonvulsant properties.[1] Changes in the lipid microenvironment can allosterically modulate receptor function, potentially explaining the broad CNS effects without necessarily involving direct high-affinity binding to the orthosteric sites of these numerous receptors.

Other Reported Pharmacological Effects

A variety of other pharmacological activities have been attributed to Emoxipin/Mexidol, including:

• Anti-stress, anxiolytic, and anticonvulsant actions.[1]
• Anti-amnestic properties.[4]
• Anti-atherogenic potential.[7]
• Cardioprotective effects.[6]

4. Pharmacokinetics (PK)

The pharmacokinetic profile of Emoxipin succinate (Mexidol) has been characterized, primarily from studies conducted in Russia.

Table 2: Key Pharmacokinetic Parameters of Emoxypine Succinate (Mexidol) in Humans

Parameter	Oral Administration	Intramuscular (IM) Administration	Intravenous (IV) Administration
Tmax (Peak Time)	~1 hour (for powder/tablets, 400-500 mg) 31	0.45-0.5 hours 27	Rapid (component of infusion)
Cmax (Peak Conc.)	3.5-4.0 µg/mL (400-500 mg dose) 31	3.5-4.0 µg/mL (400-500 mg dose) 27	Dose-dependent, part of infusion regimen
Half-life (t1/2)	2.0-2.6 hours 31	Not explicitly stated for base drug, succinate quick elim.	Succinate quick elim. 23
Mean Retention/Residence Time	4.9-5.2 hours 31	0.7-1.3 hours (MRT) 27	Not explicitly stated
Primary Excretion Route	Urine (mainly as metabolites) 27	Urine (mainly as metabolites) 27	Urine (mainly as metabolites) 27
Key Metabolites	3-hydroxypyridine phosphate, other active/inactive forms, glucuronoconjugates 27	Same as oral 27	Same as oral 27

Note: Some parameters may be for the succinate moiety or based on animal data if human data is not specified in the snippets.

Absorption

Mexidol is rapidly absorbed following oral administration, with peak plasma concentrations (Cmax​) of 3.5-4.0 µg/mL achieved within approximately 1 hour for doses of 400-500 mg.[31] After intramuscular injection, the drug is detected in plasma for up to 4 hours, with a Tmax​ of 0.45-0.5 hours and a similar Cmax​ range.[27]

Distribution

The drug distributes rapidly into organs and tissues, with a notable affinity for the brain, where it is reported to cross the blood-brain barrier.[4] Within nerve cells, Mexidol reportedly concentrates in mitochondria.[4] The mean retention time after oral administration is approximately 4.9-5.2 hours [31], while the mean residence time (MRT) following IM administration is shorter, around 0.7-1.3 hours.[27] Studies in rats indicate that the succinate component is evenly distributed in organs and tissues after IV administration of Mexidol.[23]

Metabolism

Mexidol undergoes hepatic metabolism, primarily through glucuronoconjugation.[27] Five distinct metabolites have been identified. These include 3-hydroxypyridine phosphate, which is formed in the liver and subsequently dephosphorylated; a pharmacologically active metabolite that is produced in significant quantities and detected in urine 1-2 days post-administration; another metabolite extensively excreted in urine; and two glucuronoconjugates.[27]

Excretion

Elimination of Mexidol and its metabolites is rapid and occurs mainly via the kidneys.[27] The majority of the drug is excreted in the urine as metabolites, with only a negligible amount of the unchanged drug being eliminated. The most intensive period of excretion is within the first 4 hours following oral intake.[31] The elimination half-life (t1/2​) after oral administration is approximately 2-2.6 hours.[31] Individual variability in the excretion parameters of the unchanged drug and its metabolites has been noted.[31]

The pharmacokinetic profile, characterized by rapid absorption, good distribution to target tissues including the brain and mitochondria, and relatively prompt elimination, supports its use in acute conditions or suggests the need for multiple daily doses for sustained effects in chronic settings. The presence of a pharmacologically active metabolite could extend the therapeutic window beyond what the half-life of the parent compound might suggest. The noted inter-individual variability in excretion [31] is an important consideration, as it could lead to differing therapeutic responses or side effect profiles among patients, potentially necessitating individualized dosing strategies, although specific guidance on therapeutic drug monitoring is not provided in the available information.

5. Pharmacodynamics (PD)

The pharmacodynamic effects of Emoxipin/Mexidol are diverse, reflecting its multimodal mechanism of action and impacting various physiological systems.

Central Nervous System (CNS) Effects

Mexidol is reported to exert significant nootropic, anxiolytic, anti-stress, anticonvulsant, and anti-amnestic effects.[1] Clinically, this translates to normalization of post-stress behavior, improvements in somatovegetative disorders, restoration of sleep-wake cycles, and enhanced learning and memory processes.[21] It is also suggested to reduce dystrophic and morphological changes in various brain structures.[21] These effects are underpinned by its ability to improve cerebral metabolism and blood supply, enhance microcirculation and blood rheological properties (including reducing platelet aggregation), reduce glutamate excitotoxicity, and restore neurotransmitter balance.[21]

Cardiovascular Effects

In the cardiovascular system, Mexidol exhibits hypolipidemic activity, reducing total cholesterol and low-density lipoprotein (LDL) levels.[21] It is reported to improve the functional state of ischemic myocardium by increasing collateral blood supply, aiding in the preservation of cardiomyocyte integrity and function, and restoring myocardial contractility in cases of reversible dysfunction.[7] Additionally, Mexidol enhances the antianginal activity of nitrate medications.[4]

Ophthalmological Effects

Mexidol has shown protective effects in the eye, promoting the preservation of retinal ganglion cells and optic nerve fibers in progressive neuropathies associated with chronic ischemia and hypoxia.[22] This can lead to improved functional activity of the retina and optic nerve, and an increase in visual acuity.[22]

Other Systemic Effects

The drug is described as increasing the body's overall resistance to various damaging factors, including shock, hypoxia, ischemia, cerebrovascular disorders, and intoxication from alcohol or antipsychotic agents.[21] It also stabilizes the membrane structures of blood cells, such as erythrocytes and platelets, during hemolysis.[21] In cases of acute pancreatitis, Mexidol is reported to reduce enzymatic toxemia and endogenous intoxication.[22]

The broad array of pharmacodynamic outcomes is consistent with Mexidol's fundamental mechanistic actions on oxidative stress, hypoxic response, and membrane stability. This suggests its potential as an adjunctive therapeutic agent in complex multifactorial diseases where these core cellular processes are compromised. The observed improvements in microcirculation and blood rheology, including the reduction of platelet aggregation [21], represent a significant vascular pharmacodynamic effect that likely contributes to its efficacy in ischemic conditions, complementing its direct cytoprotective actions.

6. Clinical Applications and Efficacy

Emoxipin, primarily as Mexidol, is extensively used in Russia and several CIS countries across a spectrum of medical conditions.[1] The clinical data supporting these uses predominantly originate from these regions. An overview of its key applications and reported efficacy is presented below.

Table 3: Summary of Investigated/Reported Indications and Efficacy for Emoxipin/Mexidol

Indication	Reported Efficacy/Key Findings	Type of Evidence/Study (Examples)
Acute Ischemic Stroke	Improved functional outcomes, quality of life; reduced symptoms. Part of Russian clinical recommendations (Grade A persuasiveness). 4	RCT (EPICA study) 27; Clinical guidelines 4
Chronic Brain Ischemia (CBI) / Dyscirculatory Encephalopathy	Improved cognitive, emotional, motor functions; enhanced quality of life. 2	RCT (MEMO study) 25; Clinical studies 32
Traumatic Brain Injury (TBI)	Indicated for treatment of TBI and its consequences. 22	Listed indication; Dosing regimens provided 22
Cognitive Impairment	Prevention and reduction of severity, particularly if associated with hypertension/atherosclerosis. 22	Clinical studies, Sub-analysis of MEMO study 25
Anxiety Disorders	Effective for neurotic and neurosis-like states. 22	Clinical studies; Listed indication with dosing 22
Acute Myocardial Infarction (AMI)	Used adjunctively from day 1; improves ischemic myocardium function. 7	Clinical study in ACS showing reduced angina, improved hemodynamics, increased LVEF 28
Primary Open-Angle Glaucoma (POAG)	Used adjunctively; preserves retinal ganglion cells, improves visual function. 22	Clinical studies showing improved optic nerve electrical sensitivity, visual fields, and retinal blood flow 45
Alcohol Withdrawal Syndrome	Relief of symptoms, especially neurosis-like and vegetative-vascular disorders. 22	Clinical studies showing accelerated reduction of anxiety/depression symptoms 49; Listed indication with dosing 22
Acute Antipsychotic Intoxication	Indicated for treatment. 22	Listed indication with dosing 22
ADHD (Children 6-12 years)	Reduced inattention, hyperactivity/impulsivity; improved social adaptation. 4	RCT (MEGA study) 41
Perinatal Encephalopathy (Infants 0-4 months)	Reduced neuro-reflexion irritation and depression syndromes; normalized neurosonoscopic patterns. 23	Clinical study 54
Acute Pancreatitis	Reduces enzymatic toxemia and endogenous intoxication (part of complex therapy). 22	Listed indication with dosing 22
Acute Cerebral Failure (Rehabilitation)	Under investigation. 11	Clinical Trial (NCT06221826) 11

Detailed Discussion of Efficacy by Indication

Cerebrovascular Disorders:

Emoxipin/Mexidol is prominently used in the management of various cerebrovascular disorders. In acute ischemic stroke, it is included in Russian clinical recommendations with a high level of persuasiveness (Grade A).4 Sequential therapy, involving initial intravenous administration followed by oral maintenance, has been reported as effective during the acute and early recovery phases. The EPICA study, a randomized, double-blind, placebo-controlled trial, demonstrated that Mexidol significantly reduced symptoms and functional impairment, leading to better modified Rankin Scale (mRS) scores and lower National Institutes of Health Stroke Scale (NIHSS) scores compared to placebo.27 Similar benefits in functional outcomes and quality of life have been noted in other studies.20

For chronic brain ischemia (CBI) and dyscirculatory encephalopathy, Mexidol is reported to improve cognitive functions, emotional status, and motor capabilities, thereby enhancing patients' quality of life.[2] The MEMO study, an international, multicenter, randomized, double-blind, placebo-controlled trial, specifically found that sequential therapy with Mexidol and Mexidol FORTE 250 resulted in superior improvements in Montreal Cognitive Assessment (MoCA) scores and other secondary endpoints across various age groups when compared to placebo.[25] Mexidol is also indicated for the treatment of traumatic brain injury (TBI) and its sequelae, with typical regimens involving 200-500 mg IV 2-4 times daily for 10-15 days, followed by oral administration.[22]

Cognitive Impairments and Anxiety Disorders:

Mexidol is indicated for mild to moderate cognitive disorders, particularly those associated with arterial hypertension and atherosclerosis, where it is suggested to prevent development and reduce severity.22 For anxiety disorders in the context of neurotic and neurosis-like states, Mexidol is an indicated treatment, typically administered intramuscularly at 100-300 mg/day for 14-30 days before transitioning to oral therapy.22 Studies in elderly patients with discirculatory encephalopathy have reported a reduction in the severity of asthenic and anxiety symptoms with Mexidol treatment.38

Cardiovascular Conditions:

In acute myocardial infarction (AMI), Mexidol is used adjunctively from the first day of treatment as part of a comprehensive therapeutic regimen.22 It is reported to improve the functional state of the ischemic myocardium.7 A clinical study in patients with acute coronary syndrome (ACS) demonstrated that a 10-day course of Mexidol (250 mg IV daily) reduced angina, stabilized hemodynamic parameters, decreased QT dispersion, and increased left ventricular ejection fraction.28

Ophthalmology:

Mexidol is employed in the complex therapy of primary open-angle glaucoma (POAG) across various stages.22 Intravenous infusions (300 mg daily for 2 weeks) have been shown to decrease the optic nerve electrical sensitivity threshold and widen total visual fields. A delayed vasotropic effect, manifested as increased blood flow velocity in the central retinal artery, was observed 90 days post-infusion.45 Parabulbar injections have also been utilized.47 These effects are consistent with its reported retinoprotective properties.34

Substance Abuse and Intoxication:

For alcohol withdrawal syndrome, Mexidol is used to alleviate symptoms, particularly neurosis-like and vegetative-vascular disturbances.22 A typical regimen involves 200-500 mg IV or IM, 2-3 times daily for 5-7 days.22 Studies suggest Mexidol accelerates the reduction of specific anxiety and depression symptoms associated with alcohol withdrawal.49 It is also indicated for acute intoxication with antipsychotic agents, administered at 200-500 mg/day IV for 7-14 days.22

Pediatric Applications:

Mexidol has been investigated and used in specific pediatric populations. For Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-12 years, it is reported to reduce symptoms of inattention and hyperactivity/impulsivity, thereby improving social adaptation.4 The MEGA study, a multicenter, double-blind, randomized, placebo-controlled trial, specifically assessed its efficacy and safety in this population, with a common dosage being 125 mg twice daily for 6 weeks.21 In infants (0-4 months) with perinatal encephalopathy, Mexidol (5 mg/kg injections twice daily) reportedly reduced neuro-reflexion irritation and depression syndromes and normalized neurosonoscopic findings.23

The extensive range of indications for Emoxipin/Mexidol across neurology, cardiology, psychiatry, and ophthalmology likely stems from its broad mechanistic actions targeting fundamental pathological processes like oxidative stress and hypoxia. This wide applicability, however, also invites scrutiny regarding the specificity of its effects and the consistency of evidence across these diverse conditions, particularly when assessed against the stringent, indication-specific approval pathways common in Western regulatory systems. The common theme of "sequential therapy" (IV followed by oral) in acute conditions like stroke [20] is a practical approach to leverage its rapid onset of action and pharmacokinetic profile, aiming for immediate high drug levels followed by sustained oral maintenance. The ongoing clinical trial NCT06221826, investigating Mexidol in the rehabilitation of patients with acute cerebral failure [11], represents continued research that may provide data aligning more closely with international trial registration standards, potentially facilitating broader scientific evaluation.

7. Safety and Tolerability

Emoxipin/Mexidol is generally reported in Russian literature and manufacturer's information as being well-tolerated with a favorable safety profile.[4]

Table 4: Adverse Effects of Emoxipin/Mexidol (Primarily Succinate Salt)

System Organ Class	Adverse Effect	Frequency (Typical)	Supporting Snippets
Immune System Disorders	Angioedema, Urticaria, Anaphylactic shock (for injection)	Very Rare (<0.01%)	21
Mental Disorders	Drowsiness	Very Rare (<0.01%)	21
Nervous System Disorders	Headache, Dizziness (may be related to rapid administration rate for injection)	Very Rare (<0.01%)	21
Vascular Disorders	Decreased blood pressure, Increased blood pressure (may be related to rapid administration rate for injection)	Very Rare (<0.01%)	22
Respiratory Disorders	Dry cough, Sore throat, Chest discomfort, Dyspnea (may be related to rapid administration rate for injection)	Very Rare (<0.01%)	22
Gastrointestinal Disorders	Dry mouth, Nausea, Unpleasant odor, Metallic taste, Epigastric pain/burning, Heartburn, Flatulence, Diarrhea	Very Rare (<0.01%)	21
Skin/Subcutaneous Tissue	Itching, Rash, Hyperemia	Very Rare (<0.01%)	21
General/Administration Site	Sensation of warmth (for injection)	Very Rare (<0.01%)	22

Table 5: Contraindications and Key Warnings/Precautions for Emoxipin/Mexidol

Condition/Factor	Implication	Supporting Snippets
Hypersensitivity to drug/components	Contraindication	21
Acute liver and/or kidney dysfunction	Contraindication	21
Children under 6 years (tablets)	Contraindication (insufficient data)	21
Pediatric use under 18 years (injection)	Contraindication (insufficient data)	22
Pregnancy and breastfeeding	Contraindication (insufficient data)	21
Lactose intolerance, lactase deficiency, glucose-galactose malabsorption	Contraindication (for tablets)	21
Bronchial asthma, hypersensitivity to sulfites (for injection)	Warning/Precaution	22
Tasks requiring rapid psychophysical reactions (e.g., driving)	Precaution (potential drowsiness)	21

Use in Special Populations

• Pediatrics: Official product information often cites contraindications for younger children due to insufficient data (under 6 years for tablets, under 18 for injection).[21] However, clinical investigations and listed indications exist for specific pediatric groups, such as children aged 6-12 years for ADHD [4] and infants (0-4 months) for perinatal encephalopathy.[23] This discrepancy suggests a nuanced situation where specific research may support use in certain pediatric conditions despite broader cautionary labeling.
• Pregnancy and Lactation: Mexidol is generally contraindicated during pregnancy and breastfeeding due to a lack of sufficient safety data in these populations.[21]
• Geriatrics: Clinical studies have included elderly patients, for instance, in the context of discirculatory encephalopathy, with reports of efficacy.[38] One source indicates successful use in patients older than 75 years.[4]

A key aspect of minimizing adverse effects, particularly with parenteral administration, appears to be the rate of administration. Several side effects, such as dizziness, blood pressure fluctuations, and respiratory discomfort, are noted to be potentially associated with an excessively rapid infusion rate, suggesting that slow administration is crucial for optimal tolerability.[22] Gradual discontinuation of the drug is also recommended once a stable clinical and laboratory effect has been achieved.[22]

8. Drug Interactions

Mexidol is reported to interact with several classes of drugs, generally by enhancing their effects or reducing their toxicity.

Table 6: Clinically Significant Drug Interactions with Emoxipin/Mexidol

Interacting Drug/Class	Effect of Interaction	Supporting Snippets
Benzodiazepine anxiolytics	Enhanced effect	21
Antidepressants	Enhanced effect	21
Anticonvulsants (e.g., carbamazepine)	Enhanced effect	21
Anti-Parkinsonian drugs (e.g., Levodopa)	Enhanced effect	21
Nitrates and nitrate-like products	Enhanced antianginal activity	4
Ethyl alcohol	Reduced toxic effects of alcohol	4
Antipsychotic agents	Reduced toxic effects of antipsychotics	21 (tablet); 22 (injection, for acute intoxication)
Drugs metabolized by/substrates of ABCB1 (P-gp) or SLCO1B1 (OATP1B1)	Potential for inhibition by EMHPS (Mexidol), especially in GI tract for ABCB1. Systemic inhibition unlikely.	57

Mexidol is generally considered compatible with all drugs used in the treatment of somatic diseases.[4] A significant aspect of its interaction profile is its ability to potentiate the therapeutic effects of various CNS-active drugs, including benzodiazepines, antidepressants, anticonvulsants (like carbamazepine), and anti-Parkinsonian agents (such as Levodopa). This enhancement may allow for a reduction in the dosage of these concomitant medications, potentially leading to a decrease in their side effects.[21] It also enhances the antianginal activity of nitrates [4] and is reported to reduce the toxic effects of ethyl alcohol.[4]

When administered intravenously, Mexidol solution should be diluted in 0.9% sodium chloride or 5% dextrose solution and should not be mixed in the same line with other drugs.[22]

More recent in vitro studies investigating the interaction of ethylmethylhydroxypyridine succinate (EMHPS/Mexidol) with drug transporters have shown that it is not a substrate for ABCB1 (P-glycoprotein) or SLCO1B1 (OATP1B1).[57] However, EMHPS was found to inhibit the activity of both ABCB1 and SLCO1B1, although its inhibitory potency was less than that of classic inhibitors like verapamil (for ABCB1) and rifampicin (for SLCO1B1). The succinic acid component of Mexidol did not contribute to this inhibitory activity. While the systemic inhibition of these transporters by EMHPS is predicted to be not clinically significant, the potential for inhibition of ABCB1 in the gastrointestinal tract warrants further in vivo investigation, particularly for orally co-administered drugs that are sensitive ABCB1 substrates with narrow therapeutic windows.[57]

9. Regulatory Status and Manufacturing

The regulatory standing and manufacturing landscape of Emoxipin/Mexidol are distinctly regional.

Primary Regions of Use and Regulatory Standing

Emoxipin, predominantly as Mexidol, is widely utilized in Russia and some other CIS countries.[1] It is a registered drug in Russia and Ukraine, marketed under various trade names including Mexidol, Mexicor, and Armadin Long.[3] Within the Russian healthcare system, Mexidol holds a significant position. It is included in official clinical recommendations and standards of care for several conditions, such as stroke, where it carries a high level of persuasiveness (Grade A).[4] Furthermore, its inclusion in the Russian list of Vital and Essential Drugs (ZhNVLP) underscores its perceived importance and established role.[4] This strong national endorsement contrasts with its status in many Western countries.

International Regulatory Status

Internationally, particularly in regions governed by regulatory bodies like the FDA (United States) and EMA (Europe), Emoxipin/Mexidol has not received approval for the broad range of indications for which it is used in Russia.[1] DrugBank lists Emoxypine (DB19172) as "Investigational." It notes ongoing clinical trial NCT06221826, investigating Mexidol in the rehabilitation treatment of patients with acute cerebral failure.[11] Another trial, NCT06854601 for ADHD in children, is listed as having completed Phase 3.[53] This "investigational" status in international databases for specific, often narrowly defined trials, highlights the difference from its widespread, multi-indication approval in Russia.

Manufacturers

The primary manufacturer associated with the original development of Mexidol is the Russian company Pharmasoft Pharmaceuticals.[1] Vektorpharm LLC, based in Moscow, Russia, is also listed as a manufacturer of Mexidol.[2] Additionally, other Russian entities are involved in its production, including ARMAVIR BIOFACTORY, FKP; ELLARA, LLC; MOSCOW ENDOCRINE PLANT, FSUE; and PharmFirma Sotex, CJSC.[27] The presence of multiple manufacturers for a drug termed "original" or "reference" in Russia [2] suggests a mature domestic market, likely involving generic production or multiple licensing agreements following the expiry of initial patents or under specific local regulations. The designation as a "reference drug" is typically used in the context of bioequivalence studies for generic products, confirming its long-standing market presence.

10. Conclusion and Future Perspectives

Emoxipin, principally utilized as its succinate salt Mexidol, is a synthetic pharmaceutical agent characterized by antioxidant, antihypoxic, and membrane-protective properties. Its development and extensive clinical application are predominantly concentrated in Russia and several CIS nations, where it is employed for a wide array of neurological, cardiovascular, ophthalmological, and psychiatric conditions, as well as in the management of intoxication and withdrawal syndromes.

The therapeutic efficacy of Mexidol, as reported in studies largely from these regions, appears to stem from its multimodal mechanism of action. This includes direct free radical scavenging, enhancement of endogenous antioxidant enzyme activity, modulation of the Nrf2 pathway, and specific antihypoxic contributions from its succinate moiety via metabolic support (Krebs cycle) and GPR91 receptor activation. Its membrane-stabilizing effects and modulation of neurotransmitter receptor complexes further contribute to its diverse pharmacodynamic profile. Pharmacokinetically, Mexidol exhibits rapid absorption and distribution, including penetration of the blood-brain barrier, followed by relatively swift metabolism and excretion, primarily as glucuronide conjugates.

Despite its widespread use and established role in certain national healthcare systems, including its inclusion in Russia's list of Vital and Essential Drugs and official clinical guidelines [4], Emoxipin/Mexidol has not achieved similar regulatory approval or widespread clinical adoption in Western countries. This disparity likely reflects differences in regulatory evidentiary standards, variations in clinical trial design and reporting, and potentially limited dissemination of research in globally accessible, high-impact peer-reviewed journals. The broad spectrum of its indications, while suggestive of a fundamental cytoprotective mechanism, may also present a challenge for regulatory frameworks that often favor drugs with highly specific molecular targets and narrowly defined indications.

The existing body of evidence, while substantial within its primary regions of use, would require supplementation with large-scale, multicenter randomized controlled trials (RCTs) designed and conducted according to contemporary international standards (e.g., ICH-GCP) to gain broader global acceptance. The ongoing clinical trial NCT06221826 for acute cerebral failure and the completed Phase 3 trial NCT06854601 for ADHD [11] may represent steps towards generating data that could be more widely evaluated by the international scientific community.

Future research could beneficially focus on further elucidating the specific molecular interactions underlying Mexidol's pleiotropic effects, particularly to identify dominant mechanisms relevant to specific pathologies. This could help refine its therapeutic positioning and identify patient populations most likely to benefit. Its potential as an adjunctive therapy in conditions characterized by significant oxidative stress, hypoxia, or membrane dysfunction remains an area of interest, provided its efficacy and safety can be rigorously demonstrated in well-controlled studies that meet global regulatory expectations. The case of Emoxipin/Mexidol highlights the complexities of global drug development and the impact of regional research and regulatory ecosystems on the international availability of therapeutic agents.

11. References

(References are to be formatted as per standard medical journal guidelines, listing all cited snippets. For this exercise, the snippet IDs serve as placeholders for full citations.)

.[1]

Works cited

1. Emoxypine - Wikipedia, accessed May 19, 2025, https://en.wikipedia.org/wiki/Emoxypine
2. Information about the drug Mexidol, accessed May 19, 2025, https://mexidol.ru/en/o-preparate/
3. Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes and consideration of their potential as performance enhancing drugs - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/38403950/
4. Question -answer - Mexidol, accessed May 19, 2025, https://mexidol.ru/en/vopros-otvet
5. An overview of the mechanism of action of Emoxypine and its ..., accessed May 19, 2025, https://www.researchgate.net/figure/An-overview-of-the-mechanism-of-action-of-Emoxypine-and-its-succinate-derivative_fig1_362414294
6. A modern concept of antihypoxic and antioxidant effects of mexidol ..., accessed May 19, 2025, https://www.researchgate.net/publication/331508525_A_modern_concept_of_antihypoxic_and_antioxidant_effects_of_mexidol
7. Promising effects of emoxypine and its succinate derivative in the management of various diseases-with insights on recent patent applications - PMC - PubMed Central, accessed May 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9389226/
8. Pharmacoadzor - Mexidol, accessed May 19, 2025, https://mexidol.ru/en/farmakonadzor
9. Chitin and Chitosan Compliance: Insights into FDA and EMA Guidelines - Entoplast, accessed May 19, 2025, https://www.entoplast.com/post/chitin-and-chitosan-compliance-insights-into-fda-and-ema-guidelines
10. EMA and FDA approval of regulatory starting materials - European Pharmaceutical Review, accessed May 19, 2025, https://www.europeanpharmaceuticalreview.com/article/130745/approval-of-regulatory-starting-materials/
11. Emoxipine | C8H11NO | CID 114681 - PubChem, accessed May 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Emoxipine
12. Emoxipine | C8H11NO | CID 114681 - PubChem, accessed May 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/2-Ethyl-3-hydroxy-6-methylpyridine
13. Mexidol | C8H11NO - ChemSpider, accessed May 19, 2025, https://www.chemspider.com/Chemical-Structure.102688.html
14. CAS No : 2364-75-2| Product Name : Emoxypine - API - Pharmaffiliates, accessed May 19, 2025, https://www.pharmaffiliates.com/public/en/2364-75-2-emoxypine-api-pa3236000.html
15. EMOXYPINE - precisionFDA, accessed May 19, 2025, https://precision.fda.gov/ginas/app/ui/substances/9236d794-ef41-49a0-8182-f6defbd47c84
16. Mexidol | C12H17NO5 - ChemSpider, accessed May 19, 2025, https://www.chemspider.com/Chemical-Structure.109054.html
17. 2-Ethyl-3-hydroxy-6-methylpyridine Succinate 127464-43-1 - TCI America, accessed May 19, 2025, https://www.tcichemicals.com/CA/en/p/E1069
18. Purchase 2-Ethyl-3-hydroxy-6-methylpyridine - Sarchem Labs, accessed May 19, 2025, https://www.sarchemlabs.com/product/2-ethyl-6-methyl-3-hydroxypyridine-succinate/
19. Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes and consideration of their potential as performance enhancing drugs | Request PDF - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/publication/378489338_Mexidol_Cytoflavin_and_succinic_acid_derivatives_as_antihypoxic_anti-ischemic_metabolic_modulators_and_ergogenic_aids_in_athletes_and_consideration_of_their_potential_as_performance_enhancing_drugs
20. [Experience with mexidol in neurological practice] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/30499505/
21. Instructions for Mexidol®, tablets covered with a film shell 125 mg ..., accessed May 19, 2025, https://mexidol.ru/en/kak-primenyat/instruktsiya-po-meditsinskomu-primeneniyu-lekarstvennogo-preparata-meksidol-tabletki-125-mg-30
22. Instructions of the drug Mexidol®, a solution for iv and in/m administration of 50 mg/ml 2 ml No. 10, accessed May 19, 2025, https://mexidol.ru/en/kak-primenyat/instruktsiya-po-meditsinskomu-primeneniu-lekarstvestvennogo-preparata-meksidol-dlya-vnutrivennogo-i-vnutrimyshechnogo-vveddeniya-2-ml-10
23. Pharmacokinetics of Succinate in Rats after Intravenous ... - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/37338763/
24. [The trial of the efficacy and safety of sequential therapy with Mexidol ..., accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/33244953/
25. [Efficacy of Mexidol in patients with chronic brain ischemia and ..., accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/36412160/
26. [The efficacy and safety of Mexidol Forte 250 as part of long-term ..., accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/32307431/
27. Мексидол инструкция по применению: показания ... - Видаль, accessed May 19, 2025, https://www.vidal.ru/drugs/mexidol__39927
28. Влияние мексидола на показатели инфракрасной ..., accessed May 19, 2025, https://www.mediasphera.ru/issues/kardiologiya-i-serdechno-sosudistaya-khirurgiya/2014/5/031996-6385201455
29. Emoxypine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed May 19, 2025, https://go.drugbank.com/drugs/DB19172
30. Promising effects of emoxypine and its succinate derivative in the management of various diseases-with insights on recent patent applications - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/35992374/
31. Мексидол Таблетки покрытые пленочной оболочкой 125 мг 50 шт купить по цене 543,0 руб в Москве, аналоги, заказать лекарство в интернет-аптеке: инструкция по применению, доставка на дом, accessed May 19, 2025, https://366.ru/p/meksidol-tab-p-o-125mg-50-27525/
32. [The results of the study of the efficacy and safety of mexidol in patients with chronic cerebral ischemia] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/26081329/
33. Results of the sequential use of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/publication/340787288_Results_of_the_sequential_use_of_Mexidol_and_Mexidol_Forte_250_in_patients_with_chronic_cerebral_ischemia
34. [Mexidol: the spectrum of pharmacological effects]. - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/publication/296067579_Mexidol_the_spectrum_of_pharmacological_effects
35. Combined administration of mexidol with known medicines - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/publication/333574003_Combined_administration_of_mexidol_with_known_medicines
36. Мексидол 125 мг 30 шт. таблетки, покрытые пленочной оболочкой - Apteka.ru, accessed May 19, 2025, https://apteka.ru/product/meksidol-125-mg-30-sht-tabletki-pokrytye-plenochnoj-obolochkoj-5e326f03ca7bdc00019303b6/
37. Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coronary intervention | Request PDF - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/publication/391182726_Pharmacological_treatment_and_prevention_of_ischemia-reperfusion_syndrome_in_percutaneous_coronary_intervention
38. [The assessment of the clinical efficacy, vasoactive and metabolic effects of mexidol in elderly patients with discirculatory encephalopathy] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/22611676/
39. [Effectiveness and safety of mexidol forte 250 in the sequential therapy in patients with chronic ischemia] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/33340299/
40. [The study of the efficacy and safety of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/32207723/
41. Promising Effects of Emoxypine and Its Succinate Derivative in the Management of Various DiseSes -Withs on Recent Patent Applications, accessed May 19, 2025, https://mexidol.ru/en/biblioteka/dokazatelnaya-baza/promising-effects-of-emoxypine-and-its-succinate-derivate-in-the-management-of-various-diseases-with-insiits-on-recent-patent-applications
42. Mexidol drug: areas of application, action mechanism, accessed May 19, 2025, https://mexidol.ru/en/
43. Abstracts – 57th ESCVS - Oxford Academic, accessed May 19, 2025, https://academic.oup.com/icvts/article-pdf/7/Supplement_1/S1/2602635/7-Supplement_1-S1.pdf
44. Мексидол®. Доказательная медицина: просто о сложном. - Mexidol, accessed May 19, 2025, https://mexidol.ru/ekspertnoe-mnenie-video/meksidol-dokazatelnaya-mediczina-prosto-o-slozhnom/
45. [The influence of water soluble antioxidant agent (mexidol) on optic nerve and blood flow velocity in ocular and orbital arteries in patients with primary open-angle glaucoma] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/22994106/
46. Мексидол в комплексном лечении глаукомы | Егоров Е.А., Давыдова Н.Г., Романенко И.А., Новикова Н.Д. | «РМЖ» №3 от 14.09.2011 - Rmj.ru, accessed May 19, 2025, https://www.rmj.ru/articles/oftalmologiya/Meksidol_v_kompleksnom_lechenii_glaukomy/
47. RU2351299C1 - Способ улучшения зрительных функций при первичной открытоугольной глаукоме с нормализованным офтальмотонусом - Google Patents, accessed May 19, 2025, https://patents.google.com/patent/RU2351299C1/ru
48. The effectiveness and tolerability of anti-seizure medication in alcohol withdrawal syndrome: a systematic review, meta-analysis and GRADE of the evidence - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/33822427/
49. [An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/34693691/
50. Мексидол, таблетки, покрытые пленочной оболочкой 125мг, 50 шт - Аптека в Коврове, accessed May 19, 2025, https://kovrov.aptechestvo.ru/catalog/meksidol_tbl_p_o_plenoch_125mg_50/
51. «Мексидол» от алкоголизма - действие препарата, свойства, влияние на организм, accessed May 19, 2025, https://ultra-med.ru/preparaty-dlya-lecheniya-alkogolizma/meksidol-ot-alkogolizma/
52. [Possibilities of using Mexidol in the complex therapy of mental disorders] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/32621483/
53. Attention-Deficit/Hyperactivity Disorder Completed Phase 3 Trials for Emoxypine (DB19172), accessed May 19, 2025, https://go.drugbank.com/indications/DBCOND0032306/clinical_trials/DB19172?phase=3&status=completed
54. [Efficiency of mexidol during perinatal encephalopathy in early age children] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/16052053/
55. [Effect of mexidol on clinical and biochemical parameters of perinatal hypoxia in newborn children] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/11764497/
56. EMOXYPINE SUCCINATE - Inxight Drugs, accessed May 19, 2025, https://drugs.ncats.io/drug/2R985002CT
57. Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1 - PMC, accessed May 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10674565/
58. Myocardial infarction: review of clinical trials and treatment strategies - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/9708119
59. Antiarrhythmic efficacy of combined intravenous and oral mexiletine in acute myocardial infarction. A double blind placebo-controlled study - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/6383836/
60. Novel oral medications for retinal disease: an update on clinical development - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/36943473/
61. Choroidal thickening and retinal dopamine increase in mice at high altitude - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39814194/
62. [Effects of emoxipine, reamberine and mexidol on neuropathic symptoms and a systolic function of the left ventricular myocardium in patients with diabetes mellitus and diabetic foot syndrome] - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/16320677/
63. here - gnTEAM, accessed May 19, 2025, http://gnteam.cs.manchester.ac.uk/old/epidemiology/data/specialist.txt
64. Effect of Pro- and Antioxidants on Insulin Sensitivity and Glucose Tolerance - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/publication/49760590_Effect_of_Pro-_and_Antioxidants_on_Insulin_Sensitivity_and_Glucose_Tolerance
65. KOVCHEGART Mexidol 125 mg 50 Tab - Amazon.com, accessed May 19, 2025, https://www.amazon.com/KOVCHEGART-Mexidol-125-50-Tab/dp/B0CNY1G43P
66. HSP70 Modulators for the Correction of Cognitive, Mnemonic, and Behavioral Disorders After Prenatal Hypoxia - PMC - PubMed Central, accessed May 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12025304/
67. Mexidol Anxiolytic Medication Overview - Ontosight.ai, accessed May 19, 2025, https://ontosight.ai/glossary/term/mexidol-anxiolytic-medication-overview--67a0da0d6c3593987a502c95
68. The effect of ethylmethylhydroxypyridine succinate on the parameters of chronic neuroinflammation and plastic processes in the brain of old rats during course of dexamethasone administration - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/publication/385142273_The_effect_of_ethylmethylhydroxypyridine_succinate_on_the_parameters_of_chronic_neuroinflammation_and_plastic_processes_in_the_brain_of_old_rats_during_course_of_dexamethasone_administration